Accepted for/Published in: Journal of Medical Internet Research
Date Submitted: Jun 24, 2021
Date Accepted: Dec 19, 2021
Date Submitted to PubMed: Dec 24, 2021
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Development and validation of simplified machine learning algorithms to predict prognosis of hospitalized COVID-19 patients: a multi-center, retrospective study
ABSTRACT
Background:
The current COVID-19 pandemic is unprecedented; under resource-constrained setting, predictive algorithms can help to stratify disease severity, alerting physicians of high-risk patients, however there are few risk scores derived from a substantially large EHR dataset, using simplified predictors as input.
Objective:
To develop and validate simplified machine learning algorithms which predicts COVID-19 adverse outcomes, to evaluate the AUC (area under the receiver operating characteristic curve), sensitivity, specificity and calibration of the algorithms, to derive clinically meaningful thresholds.
Methods:
We conducted machine learning model development and validation via cohort study using multi-center, patient-level, longitudinal electronic health records (EHR) from OptumĀ® COVID-19 database which provides anonymized, longitudinal EHR from across US. The models were developed based on clinical characteristics to predict 28-day in-hospital mortality, ICU admission, respiratory failure, mechanical ventilator usages at inpatient setting. Data from patients who were admitted prior to Sep 7, 2020, is randomly sampled into development, test and validation datasets; data collected from Sep 7, 2020 through Nov 15, 2020 was reserved as prospective validation dataset.
Results:
Of 3.7M patients in the analysis, a total of 585,867 patients were diagnosed or tested positive for SARS-CoV-2; and 50,703 adult patients were hospitalized with COVID-19 between Feb 1 and Nov 15, 2020. Among the study cohort (N=50,703), there were 6,204 deaths, 9,564 ICU admissions, 6,478 mechanically ventilated or EMCO patients and 25,169 patients developed ARDS or respiratory failure within 28 days since hospital admission. The algorithms demonstrated high accuracy (AUC = 0.89 (0.89 - 0.89) on validation dataset (N=10,752)), consistent prediction through the second wave of pandemic from September to November (AUC = 0.85 (0.85 - 0.86) on post-development validation (N= 14,863)), great clinical relevance and utility. Besides, a comprehensive 386 input covariates from baseline and at admission was included in the analysis; the end-to-end pipeline automates feature selection and model development process, producing 10 key predictors as input such as age, blood urea nitrogen, oxygen saturation, which are both commonly measured and concordant with recognized risk factors for COVID-19.
Conclusions:
The systematic approach and rigorous validations demonstrate consistent model performance to predict even beyond the time period of data collection, with satisfactory discriminatory power and great clinical utility. Overall, the study offers an accurate, validated and reliable prediction model based on only ten clinical features as a prognostic tool to stratifying COVID-19 patients into intermediate, high and very high-risk groups. This simple predictive tool could be shared with a wider healthcare community, to enable service as an early warning system to alert physicians of possible high-risk patients, or as a resource triaging tool to optimize healthcare resources. Clinical Trial: N/A
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.